Patricia Lie, CPA, CA, Promoted to Vice President of Finance and AdministrationToronto, OntarioFebruary 17, 2016SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF),
a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced the following management changes. On the recommendation of President and CEO Andrew Morris, SQI’s Board of Directors has approved the promotion of Ms. Patricia Lie to Vice President Finance and Administration replacing Lennie Ryer who has left the Company as Chief Financial Officer, effective February 15, 2016.
“The extensive experience Patricia has built during her career and over her five years at SQI is well-aligned with our financial and commercialization objectives”, said Andrew Morris, CEO of SQI Diagnostics. “Patricia’s contributions as an integral member of the SQI management team will continue to be very valuable as we transition to profitability and our financial profile changes accordingly”
Ms. Lie brings over 20 years of financial and strategic management experience and for the past five years Ms. Lie has held the position of Director of Finance and Administration at SQI. Prior to joining SQI, Ms. Lie was Professor of Business (Accounting) at Sheridan College; held various roles at Toronto Dominion Bank Financial Group following five years at PwC LLP, a Canadian public audit firm.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit sqidiagnostics.com.
Investor Relation Contact:
Chief Executive Officer
416.674.9500 ext. 229
This news release contains certain forward-looking statements, including, without limitation, statements containing the words “will”, “expects”, “intends” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to risks related to the failure to obtain necessary regulatory approvals, general economic and market segment conditions, and international risk and currency exchange, agreements and future agreements to sell our products, the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business, the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits, the acceleration of our revenue ramp, general economic and market segment conditions, competitor activity, technology changes and regulatory approvals. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.